What Faverin Treats: Main Uses and Benefits

The therapeutic application of Faverin (Fluvoxamine) focuses on specific symptom clusters within the neuropsychiatric domain, and is commonly used for the management of Major Depressive Episode and Obsessive-Compulsive Disorder (OCD).

The medication is generally utilized for managing the challenging, chronic manifestations of conditions characterized by recurrent, unwanted obsessions and time-consuming, ritualized compulsions. It is also relevant when symptoms cluster into patterns of excessive anxiety and persistent low mood, such as those seen in Social Anxiety Disorder and Major Depressive Disorder.

“Faverin is applied in clinical settings marked by increased discomfort or tension, relevant when supportive symptom management is appropriate.”

The key therapeutic benefit is providing support that helps ease the overall symptom load of these severe, disruptive symptoms, particularly during episodes of heightened discomfort. This provides supportive relief when symptoms interfere with routine activities and may help patients cope more steadily with difficult episodes. It is relevant across therapeutic areas where short-term symptom management is appropriate, used when symptoms interfere with daily stability, and may also assist with core physical symptoms related to systemic imbalance.

Quick Fact: Provides symptomatic support for Obsessive Thoughts and Compulsive Urges

Regulatory References

1. European Medicines Agency Scientific Conclusions

Eligibility Map: Official Regulatory Information

The eligibility profile for Faverin (Fluvoxamine) is defined by mandatory population exclusions and specific conditions documented in regulatory labeling.

Contraindicated Populations

Fluvoxamine is absolutely contraindicated in patients with a history of hypersensitivity to the drug. It must not be used concomitantly with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping an MAOI. Co-administration is also prohibited with specific medications, including Tizanidine, Pimozide, Ramelteon, Thioridazine, and Alosetron, as stated in the official Prescribing Information.

Age-Group and Condition Restrictions

The medicine is approved for adults for Major Depressive Episode and Obsessive-Compulsive Disorder (OCD), but pediatric use is strictly limited. Use is not established for children under 8 years of age. For those aged 8 to 17 years, use is approved only for OCD.

Patients with unstable epilepsy are advised to avoid use. Individuals with hepatic impairment are eligible but require conditional use, as decreased drug clearance is expected. Restricted use also applies to late-term pregnant patients due to documented risks of neonatal complications, and to nursing mothers as the drug is secreted in human breast milk.

Interactions with other medicines and products

The interaction profile of Fluvoxamine (Faverin) is primarily characterized by its potent inhibition of multiple Cytochrome P450 (CYP) enzymes, particularly CYP1A2 and CYP2C19. This inhibition can significantly raise the plasma levels of co-administered medicines metabolized by these enzymes, necessitating dose adjustments or leading to contraindications.

Contraindicated Combinations

Co-administration is strictly contraindicated with specific narrow therapeutic index drugs and other agents that may cause serious adverse reactions. This includes Monoamine Oxidase Inhibitors (MAOIs), requiring a two-week washout period when switching between treatments. Other contraindicated medicines include Tizanidine, Pimozide, Alosetron, and Ramelteon, due to the risk of toxicity from increased plasma concentrations.

Combinations Requiring Caution

Combining Fluvoxamine with other serotonergic agents (e.g., Triptans, SSRIs, Lithium) requires caution due to the documented risk of Serotonin Syndrome. Drugs that interfere with blood clotting, such as NSAIDs, Aspirin, and Warfarin, may increase the risk of bleeding. Medicines like Clozapine, Mexiletine, and some Tricyclic Antidepressants that are CYP substrates may require reduced dosage when co-administered. The consumption of alcohol is advised to be avoided, and intake of caffeine should be minimized.

How Faverin Works — Mechanism of Action

Selective Serotonin Reuptake Inhibition (SERT)

Faverin's primary action is the selective inhibition of the serotonin transporter (SERT), the protein responsible for clearing serotonin (5-HT) from the synaptic cleft. By blocking SERT, the drug prevents the reuptake of 5-HT into the presynaptic neuron, causing an increase in the concentration and duration of serotonin available to stimulate postsynaptic receptors. This sustained increase in serotonergic activity induces long-term neuroadaptive changes within neural circuits that modulate dysregulated signaling patterns in the central nervous system.

Dual Action via Sigma-1 Receptor (sigma1R) Agonism

Faverin also acts as an agonist at the intracellular Sigma-1 Receptor (sigma1R), a protein chaperone located primarily at the mitochondrial-associated endoplasmic reticulum membrane. Activation of sigma1R is separate from the serotonin mechanism and is involved in modulating cellular stress responses, regulating calcium flux, and influencing inflammatory pathways (e.g., NF-kappa B signaling) within neurons. This sigma1R agonism impacts cellular pathways associated with neuroprotection and neuroplasticity, contributing to the modulation of overall neuronal function in the central nervous system.

How to Use Faverin (Fluvoxamine)

This guide outlines the proper administration and dosing instructions for Faverin (fluvoxamine maleate).

Faverin is administered orally and is available as immediate-release (IR) film-coated tablets (e.g., 25 mg, 50 mg, 100 mg) and extended-release (ER) capsules.

Procedural Guidelines

1. Swallowing: Immediate-release tablets should be swallowed whole with water; if scored, they may be split. Extended-release capsules must be swallowed whole and must not be crushed, broken, or chewed.
2. Divided Dosing: For immediate-release tablets, doses exceeding 150 mg per day must be divided and taken in two or three administrations, with the larger portion typically given at bedtime.
3. Special Populations: A lower starting dose and slower titration are recommended for elderly patients and those with hepatic (liver) impairment.
4. Discontinuation: To minimize potential withdrawal symptoms, Faverin must be discontinued gradually. The dose should be reduced over a period of at least one to two weeks, as directed by a healthcare provider.

Standard protocols establish requirements for titration, dose division, and safe cessation of the medicine.

Research Evidence / Overview of Studies for Faverin (Fluvoxamine)

Evidence for Use in Obsessive-Compulsive Disorder (OCD)

Research has been conducted for Fluvoxamine in Obsessive-Compulsive Disorder (OCD), primarily using short-term, randomized controlled trials (RCTs). These studies involved comparing the medication against an inactive placebo or, in some cases, against an older active treatment. Trials primarily included adults and also explored pediatric patients aged eight years and older. The central research outcome was measuring symptom changes using standardized tools like the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), which is used in research exploring how symptoms change over time related to compulsive urges and obsessive thoughts.

Studies reported that the patterns of symptom change measured in the Fluvoxamine groups were often different from those observed in the placebo groups during the initial 10- to 12-week treatment period. Systematic reviews and meta-analyses of this evidence compile findings from multiple trials.

Evidence for Major Depressive Episodes and Social Anxiety

Fluvoxamine was studied for both Major Depressive Episodes (MDE) and Social Anxiety Disorder (SAD). For MDE, research involved short-term RCTs, often lasting six to eight weeks, which included comparisons to placebo and other common antidepressants. Analyses describe that the measured changes in Fluvoxamine groups were similar to the patterns observed with other common antidepressants included in the comparisons.

The research is also supported by randomized, placebo-controlled trials primarily including adult outpatients with Social Anxiety Disorder. These studies measured outcomes reflecting daily functioning and changes in specific anxiety scales over periods of about 12 weeks.

Key Limitations and Uncertainties in the Research

A key limitation noted in the research is that follow-up duration in many core randomized trials was short. Long-term effects are not fully established based on extended randomized, placebo-controlled trials, meaning there is limited information for outcomes that span multiple years. Furthermore, data for certain specific groups, such as individuals with certain comorbid conditions or the oldest adult populations, remain insufficient.

Common questions about Faverin (FAQ)

Q: What should I do if I miss a dose of Faverin?

Regulatory documents typically provide instructions for managing a missed dose. The general guidance is to take the dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, it is typically advised to skip the missed dose and resume the regular schedule. Two doses should not be taken together to make up for a missed one.

Q: Is it safe to take Faverin if I'm pregnant or breastfeeding?

Official product information states that Fluvoxamine is known to be secreted into human breast milk. For pregnant individuals, documented risks include the potential for complications, such as persistent pulmonary hypertension of the newborn (PPHN), when exposure occurs late in the third trimester. The decision to use this medication during pregnancy or breastfeeding requires a careful review of the risks and benefits, which should be done in consultation with a healthcare provider.

Q: How long does it typically take for Faverin to start working or for me to feel a difference?

Official product information indicates that the medicine typically reaches steady-state plasma concentrations (a consistent level in the bloodstream) within approximately 5 to 10 days after beginning treatment. However, the time required to feel a noticeable clinical difference or full therapeutic effect on symptoms may be longer, often requiring several weeks to months of consistent treatment.

Q: Is Faverin a controlled substance?

According to official regulatory labeling, Fluvoxamine (the active ingredient in Faverin) is not classified as a controlled substance under the U.S. Controlled Substances Act.

Q: Can Faverin be used for people under the age of 8?

Official product information states that Faverin is not approved for use in children younger than 8 years of age. For pediatric patients between 8 and 17 years old, the drug's approved use is strictly limited to the treatment of Obsessive-Compulsive Disorder (OCD).

How to Store and Dispose of Faverin (Fluvoxamine Maleate)

Faverin tablets must be stored according to specific regulatory requirements to maintain product stability and effectiveness.

Official Storage Conditions

Disposal Instructions

Expired or unused Faverin must be managed as pharmaceutical waste. Official instructions state that unused product should be returned to a pharmacist for disposal or handled according to a healthcare professional's advice. Disposal must comply with all local regulations.